<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03418168</url>
  </required_header>
  <id_info>
    <org_study_id>19353</org_study_id>
    <nct_id>NCT03418168</nct_id>
  </id_info>
  <brief_title>A Study of Molidustat for Treatment of Renal Anemia in Peritoneal Dialysis Subjects</brief_title>
  <acronym>MIYABI PD</acronym>
  <official_title>An Open-label, Multicenter Study to Investigate the Efficacy and Safety of Oral Molidustat in Peritoneal Dialysis Subjects With Renal Anemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bayer</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the efficacy and safety of molidustat in peritoneal
      dialysis subjects with renal anemia
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 22, 2018</start_date>
  <completion_date type="Anticipated">November 9, 2019</completion_date>
  <primary_completion_date type="Anticipated">October 5, 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Responder rate: proportion of responders among the subjects</measure>
    <time_frame>Week 30 to 36</time_frame>
    <description>Responder is defined as meeting all of the following criteria:
(i) Mean of the Hb levels in the target range (ii) ≥ 50% of the Hb levels in the target range (iii) No rescue treatment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean Hb (Hemoglobin) level</measure>
    <time_frame>Week 30 to 36</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in mean Hb level</measure>
    <time_frame>Baseline and Week 30 to 36</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of rise in Hb (Hemoglobin) level (g/dL/week)</measure>
    <time_frame>Up to 8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of rise in Hb (Hemoglobin) level (g/dL/week)</measure>
    <time_frame>Up to 4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects who meet each component of the response</measure>
    <time_frame>Week 30 to 36</time_frame>
    <description>Response:
(i) Mean of the Hb levels in the target range (ii) ≥ 50% of the Hb levels in the target range (iii) No rescue treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hb level</measure>
    <time_frame>Baseline and Up to Week 36</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Hb level</measure>
    <time_frame>Baseline and Up to Week 36</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects with mean hemoglobin levels are in the target range</measure>
    <time_frame>Week 30 to 36</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects with mean hemoglobin levels are above the target range</measure>
    <time_frame>Week 30 to 36</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects with mean hemoglobin levels are below the target range</measure>
    <time_frame>Week 30 to 36</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects with hemoglobin levels in the target range</measure>
    <time_frame>Up to 36 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects with hemoglobin levels above the target range</measure>
    <time_frame>Up to 36 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects with hemoglobin levels below the target range</measure>
    <time_frame>Up to 36 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects whose maximum rise in Hb between each consecutive visits is above 0.5 g/dL/week</measure>
    <time_frame>Up to 36 weeks</time_frame>
    <description>Defined as change in Hb level / duration between two visits (weeks)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of days in the target Hb range during the evaluation period</measure>
    <time_frame>Week 30 to 36</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of days in the target Hb range during the treatment period</measure>
    <time_frame>Up to 36 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of rise in Hb level (g/dL/week) between each consecutive visits</measure>
    <time_frame>Up to 36 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Hb levels in target range during the evaluation period</measure>
    <time_frame>Week 30 to 36</time_frame>
    <description>Defined as the number of measurements in the target range / number of measurements x 100 [%])</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Hb levels in target range during the treatment period</measure>
    <time_frame>Up to 36 weeks</time_frame>
    <description>Defined as the number of measurements in the target range / number of measurements x 100 [%])</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects who received at least one rescue treatment</measure>
    <time_frame>Up to 36 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with serious adverse events</measure>
    <time_frame>Up to 36 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum concentration (Cmax) of Molidustat</measure>
    <time_frame>Baseline, Week 8, Wee16 and Week 36</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the concentration-time curve (AUC) of Molidustat</measure>
    <time_frame>Baseline, Week 8, Wee16 and Week 36</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>EPO (Erythropoietin) serum concentration of Molidustat</measure>
    <time_frame>Baseline, Week 8, Wee16 and Week 36</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Anemia and Renal Insufficiency, Chronic</condition>
  <arm_group>
    <arm_group_label>Molidustat (BAY85-3934)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Molidustat group</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Molidustat (BAY85-3934)</intervention_name>
    <description>Starting dose of molidustat once daily (OD) will be titrated based on the subject's Hb (Hemoglobin) response</description>
    <arm_group_label>Molidustat (BAY85-3934)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subject with end-stage kidney disease (ESKD) on peritoneal dialysis prior to
             assignment and not expected to start maintenance dialysis (e.g., hemodialysis,
             hemodiafiltration) other than peritoneal dialysis during the study period

          -  Body weight &gt; 40 and ≤ 160 kg at screening

          -  Male or female subject ≥ 20 years of age at screening

          -  At least one kidney

          -  Subjects who meet one of the 1 or 2 following criteria

               -  Subjects untreated with ESA at assignment: Mean of the last 2 Hb level (central
                  laboratory measurement) during the screening period must be ≥ 8.0 and &lt; 11.0 g/dL
                  (2 measurements must be taken ≥ 2 days apart and the difference between the 2
                  measurements must be &lt; 1.2 g/dL) with the last screening Hb measurement within 14
                  days prior to study drug assignment

               -  Subjects pre treated with ESA at assignment: Mean of the last 2 Hb level (central
                  laboratory measurement) during the screening period must be ≥ 10.0 and &lt; 13.0
                  g/dL (2 measurements must be taken ≥ 2 days apart and the difference between the
                  2 measurements must be &lt; 1.2 g/dL) with the last screening Hb measurement within
                  14 days prior to study drug assignment

          -  Subjects who meet one of the 1 or 2 following criteria

               -  Subjects untreated with ESA at assignment: Subject with ESKD on peritoneal
                  dialysis for at least 2 weeks prior to assignment. AND. Subject not received ESA
                  for 8 weeks prior to assignment. OR. In case of the patient washed out from ESAs,
                  when mean of the last 2 Hb level (at least 2 central laboratory measurements must
                  be taken ≥ 2 days apart) has decrease to ≥ 0.5g/dL from the Hb level (central
                  laboratory measurement) after the last ESA administration, AND the interval from
                  the last ESA administration to the study drug assignment should be over 2 week
                  for epoetin-alpha/beta, 4 weeks for darbepoetin alpha or epoetin beta pegol

               -  Subjects pre treated with ESA at assignment:

                    -  Subject with ESKD on peritoneal dialysis for at least 12 weeks prior to
                       assignment

                    -  Subject treated with ESA by IV or SC within 8 weeks prior to assignment

                    -  Treated with 2 or 4 weekly dose of darbepoetin alfa, 4 weekly dose of
                       epoetin beta pegol, OR 3 times per week, twice per week, weekly or bi-weekly
                       dose of epoetin alfa/beta, and having had no more than one dose change
                       within 8 weeks prior to assignment

        Exclusion Criteria:

          -  New York Heart Association (NYHA) Class III or IV congestive heart failure

          -  History of cardio- (cerebro-) vascular events (e.g., unstable angina, myocardial
             infarction, stroke, pulmonary thromboembolism, and acute limb ischemia) within 6
             months prior to randomization

          -  Sustained and poorly controlled arterial hypertension (defined as systolic BP≥ 180mmHg
             or diastolic BP ≥ 110mmHg) or hypotension (defined as systolic BP &lt; 90mmHg) at
             randomization

          -  Proliferative choroidal or retinal disease, such as neovascular age-related macular
             degeneration or proliferative diabetic retinopathy requiring invasive treatment (e.g.,
             intraocular injections or laser photocoagulation)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Bayer Clinical Trials Contact</last_name>
    <phone>(+) 1-888-8422937</phone>
    <email>clinical-trials-contact@bayer.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>For trial location information (Phone Menu Options '3' or '4')</last_name>
    <phone>(+)1-888-84 22937</phone>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Kainan Hospital</name>
      <address>
        <city>Yatomi</city>
        <state>Aichi</state>
        <zip>498-8502</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ehime Prefectural Central Hospital</name>
      <address>
        <city>Matsuyama</city>
        <state>Ehime</state>
        <zip>790-0024</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Kokura Memorial Hospital</name>
      <address>
        <city>Kitakyushu</city>
        <state>Fukuoka</state>
        <zip>802-8555</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>JCHO Kyusyu Hospital</name>
      <address>
        <city>Kitakyushu</city>
        <state>Fukuoka</state>
        <zip>806-8501</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Kurume University Hospital</name>
      <address>
        <city>Kurume</city>
        <state>Fukuoka</state>
        <zip>830-0011</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Elm Grove Clinic</name>
      <address>
        <city>Sapporo</city>
        <state>Hokkaido</state>
        <zip>003-0814</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Kobe City Medical Center General Hospital</name>
      <address>
        <city>Kobe</city>
        <state>Hyogo</state>
        <zip>650-0047</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Fujisawa City Hospital</name>
      <address>
        <city>Fujisawa</city>
        <state>Kanagawa</state>
        <zip>251-8550</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Shonan Kamakura General Hospital</name>
      <address>
        <city>Kamakura</city>
        <state>Kanagawa</state>
        <zip>247-8533</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Toranomon Hospital Kajigaya</name>
      <address>
        <city>Kawasaki</city>
        <state>Kanagawa</state>
        <zip>213-8587</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Showa University Fujigaoka Hospital</name>
      <address>
        <city>Yokohama</city>
        <state>Kanagawa</state>
        <zip>227-8501</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Tohoku Medical and Pharmaceutical University Hospital</name>
      <address>
        <city>Sendai</city>
        <state>Miyagi</state>
        <zip>983-8512</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Niigata Prefectural Shibata Hospital</name>
      <address>
        <city>Shibata</city>
        <state>Niigata</state>
        <zip>957-8588</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>National Hospital Organization Beppu Medical Center</name>
      <address>
        <city>Beppu</city>
        <state>Oita</state>
        <zip>874-0011</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Okinawa prefectural Chubu Hospital</name>
      <address>
        <city>Uruma</city>
        <state>Okinawa</state>
        <zip>904-2293</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Fuchu Hospital</name>
      <address>
        <city>Izumi</city>
        <state>Osaka</state>
        <zip>594-0076</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Fukui-ken Saiseikai Hospital</name>
      <address>
        <city>Fukui</city>
        <zip>918-8503</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Kyushu University Hospital</name>
      <address>
        <city>Fukuoka</city>
        <zip>812-8582</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Fukuoka University Hospital</name>
      <address>
        <city>Fukuoka</city>
        <zip>814-0180</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Japanese Red Cross Fukuoka Hospital</name>
      <address>
        <city>Fukuoka</city>
        <zip>815-8555</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Fukushima Medical University Hospital</name>
      <address>
        <city>Fukushima</city>
        <zip>960-1295</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Asahi University Hospital</name>
      <address>
        <city>Gifu</city>
        <zip>500-8523</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>National Hospital Organization Kyoto Medical Center</name>
      <address>
        <city>Kyoto</city>
        <zip>612-8555</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Nara Prefecture General Medical Center</name>
      <address>
        <city>Nara</city>
        <zip>631-0846</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Niigata City General Hospital</name>
      <address>
        <city>Niigata</city>
        <zip>950-1197</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Japanese Red Cross Oita Hospital</name>
      <address>
        <city>Oita</city>
        <zip>870-0033</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Osaka General Medical Center</name>
      <address>
        <city>Osaka</city>
        <zip>558-8558</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 26, 2018</study_first_submitted>
  <study_first_submitted_qc>January 26, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">February 1, 2018</study_first_posted>
  <last_update_submitted>April 27, 2018</last_update_submitted>
  <last_update_submitted_qc>April 27, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 30, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anemia</mesh_term>
    <mesh_term>Renal Insufficiency</mesh_term>
    <mesh_term>Renal Insufficiency, Chronic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

